Factors affecting the non-publication of clinical trials of prevalent urological cancer.

Clinical trials Kidney neoplasms Neoplasms Prostate neoplasms Urinary bladder neoplasms

Journal

World journal of urology
ISSN: 1433-8726
Titre abrégé: World J Urol
Pays: Germany
ID NLM: 8307716

Informations de publication

Date de publication:
22 Jul 2024
Historique:
received: 07 03 2024
accepted: 20 06 2024
medline: 22 7 2024
pubmed: 22 7 2024
entrez: 22 7 2024
Statut: epublish

Résumé

Clinical trials (CTs) are critical in understanding and managing cancer. However, despite being completed, CT results are often unpublished, compromising the ability to glean useful information from them. This study aimed to evaluate factors influencing the non-publication of urological oncology clinical trials. We conducted a comprehensive search of ClinicalTrials.gov to identify CTs focused on urological cancers completed between 2000 and 2020. We used the National Clinical Trial (NCT) identifier number to check whether the trial was published. 9,145 oncology CTs were conducted between 2000 and 2020, of which 8.39% (n = 767) focused on urological cancers, and 47.2% (n = 362) of these trials remained unpublished. Univariable analysis revealed that trials with a sample size of less than 50 and phase 4 were significantly associated with non-publication p < 0.001. In contrast, trials involving triple masking, a higher number of agents, and those conducted in High-Income Countries were associated with a higher likelihood of publication p < 0.05. Multivariable analysis demonstrated that trials enrolling more than 50 patients and employing three or more agents, along with triple and quadruple masking, had higher odds of being published (OR = 1.62; 95%CI (1.22-2.16), 1.89; 95%CI (1.10-3.27), 3.04; 95%CI (1.44-6.44), 5.62; 95%CI (1.72-18.37), and 5.41; 95%CI (1.76-16.67), p < 0.05, respectively). However, trials conducted in low-middle-income Countries had lower odds of publication (OR = 0.26; 95%CI (0.08-0.87), p = 0.02). We found that almost one-half (47.2%) of all completed urologic oncology clinical trials are not published in a PubMed-indexed journal. This non-publication rate represents a significant loss of scientific knowledge and progress. We identified several key variables including sample size.

Identifiants

pubmed: 39037516
doi: 10.1007/s00345-024-05135-6
pii: 10.1007/s00345-024-05135-6
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

426

Informations de copyright

© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Références

Zi H, He SH, Leng XY et al (2021) Global, regional, and national burden of kidney, bladder, and prostate cancers and their attributable risk factors, 1990–2019. Mil Med Res 8(1):60. https://doi.org/10.1186/s40779-021-00354-z
doi: 10.1186/s40779-021-00354-z pubmed: 34819142 pmcid: 8611255
Sackett DL (1997) Evidence-based medicine. Semin Perinatol 21(1):3–5. https://doi.org/10.1016/S0146-0005(97)80013-4
doi: 10.1016/S0146-0005(97)80013-4 pubmed: 9190027
Kazdin AE (2008) Evidence-based treatment and practice: new opportunities to bridge clinical research and practice, enhance the knowledge base, and improve patient care. Am Psychol 63(3):146–159. https://doi.org/10.1037/0003-066X.63.3.146
doi: 10.1037/0003-066X.63.3.146 pubmed: 18377105
Selby P, Autier P (2011) The impact of the process of clinical research on health service outcomes. Ann Oncol 22:vii5–vii9. https://doi.org/10.1093/annonc/mdr419
doi: 10.1093/annonc/mdr419 pubmed: 22039145
Hopewell S, Loudon K, Clarke MJ, Oxman AD, Dickersin K (2009) Publication bias in clinical trials due to statistical significance or direction of trial results. Cochrane Database Syst Reviews 2010(1). https://doi.org/10.1002/14651858.MR000006.pub3
Ross JS, Mulvey GK, Hines EM, Nissen SE, Krumholz HM (2009) Trial publication after Registration in ClinicalTrials.Gov: a cross-sectional analysis. PLoS Med 6(9):e1000144. https://doi.org/10.1371/journal.pmed.1000144
doi: 10.1371/journal.pmed.1000144 pubmed: 19901971 pmcid: 2728480
Ross JS, Mocanu M, Lampropulos JF, Tse T, Krumholz HM (2013) Time to publication among completed clinical trials. JAMA Intern Med 173(9):825. https://doi.org/10.1001/jamainternmed.2013.136
doi: 10.1001/jamainternmed.2013.136 pubmed: 23460252 pmcid: 3691813
World Economic Outlook, October 2022
Khan MS, Shahid I, Asad N et al (2021) Discontinuation and non-publication of heart failure randomized controlled trials: a call to publish all trial results. ESC Heart Fail 8(1):16–25. https://doi.org/10.1002/ehf2.13099
doi: 10.1002/ehf2.13099 pubmed: 33191637
Chen YP, Liu X, Lv JW et al (2016) Publication status of contemporary oncology randomised controlled trials worldwide. Eur J Cancer 66:17–25. https://doi.org/10.1016/j.ejca.2016.06.010
doi: 10.1016/j.ejca.2016.06.010 pubmed: 27522246
Khatib R, McKee M, Shannon H et al (2016) Availability and affordability of cardiovascular disease medicines and their effect on use in high-income, middle-income, and low-income countries: an analysis of the PURE study data. Lancet 387(10013):61–69. https://doi.org/10.1016/S0140-6736(15)00469-9
doi: 10.1016/S0140-6736(15)00469-9 pubmed: 26498706
Grover S, Xu M, Jhingran A et al (2017) Clinical trials in low and middle-income countries — successes and challenges. Gynecol Oncol Rep 19:5–9. https://doi.org/10.1016/j.gore.2016.11.007
doi: 10.1016/j.gore.2016.11.007 pubmed: 28004030
Wells JC, Sharma S, Del Paggio JC et al (2021) An analysis of contemporary Oncology Randomized clinical trials from Low/Middle-Income vs high-income countries. JAMA Oncol 7(3):379. https://doi.org/10.1001/jamaoncol.2020.7478
doi: 10.1001/jamaoncol.2020.7478 pubmed: 33507236
Sakpal TV (2010) Sample size estimation in clinical trial. Perspect Clin Res 1(2):67–69
doi: 10.4103/2229-3485.71856 pubmed: 21829786 pmcid: 3148614
Lundh A, Lexchin J, Mintzes B, Schroll JB, Bero L (2017) Industry sponsorship and research outcome. Cochrane Database Syst Reviews 2017(2). https://doi.org/10.1002/14651858.MR000033.pub3
Dickersin K, Chan S, Chalmersx TC, Sacks HS, Smith H (1987) Publication bias and clinical trials. Control Clin Trials 8(4):343–353. https://doi.org/10.1016/0197-2456(87)90155-3
doi: 10.1016/0197-2456(87)90155-3 pubmed: 3442991
Nair A (2019) Publication bias - importance of studies with negative results! Indian J Anaesth 63(6):505. https://doi.org/10.4103/ija.IJA_142_19
doi: 10.4103/ija.IJA_142_19 pubmed: 31263309 pmcid: 6573059
DeVito NJ, Goldacre B (2019) Catalogue of bias: publication bias. BMJ Evid Based Med 24(2):53–54. https://doi.org/10.1136/bmjebm-2018-111107
doi: 10.1136/bmjebm-2018-111107 pubmed: 30523135

Auteurs

Abdulrahman Alhajahjeh (A)

Department of Internal Medicine, King Hussein Cancer Center (KHCC), Amman, Jordan.
School of Medicine, University of Jordan, Amman, Jordan.

Majedah Hmeidan (M)

Abdali Hospital, Amman, Jordan.

Ahmed A Abdulelah (AA)

Edinburgh Medical School, The University of Edinburgh, Edinburgh, UK.

Israa Al-Nezaa (I)

School of Medicine, University of Jordan, Amman, Jordan.

Faris Al-Abbadi (F)

Edinburgh Medical School, The University of Edinburgh, Edinburgh, UK.

Ryan W Dobbs (RW)

Cook County Health & Hospitals, Chicago, USA.

Zahi Abdul Sater (ZA)

Global Health Institute, American University of Beirut, Beirut, Lebanon.
College of Public Health, Phoenicia University, Mazraat El Daoudiyeh, Lebanon.

Bashir Al Hussein Al Awamlh (BAH)

Department of Urology, Vanderbilt University Medical Center, Nashville, TN, USA.

David I Lee (DI)

Department of Urology, University of California, Irvine Medical Center, Irvine, CA, UK.

Mohammed Shahait (M)

School of Medicine, University of Sharjah, Sharjah, UAE. mshahait@yahoo.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH